RPTR-147:2 / Repertoire - LARVOL DELTA

KEYNOTE KN-948: RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (clinicaltrials.gov) - P1/2 | N=23 | Terminated | Sponsor: Repertoire Immune Medicines | Trial completion date: Jul 2026 ➔ Oct 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2026 ➔ Sep 2022; Development program terminated

Combination therapy • Trial completion date • Trial primary completion date • Trial termination • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck